Vaccine injected into tumors plus immunotherapy for advanced cancers
Part of Cancer clinical trials.
This Phase 1 trial tests a cancer vaccine (VAX014) injected directly into a tumor, given alone at first and then with an immune checkpoint medicine (nivolumab or pembrolizumab). It aims to see how well this approach is tolerated and may help shrink advanced solid tumors after other treatments stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give informed consent
- You have a confirmed advanced (locally advanced or metastatic) solid tumor on scans/pathology
- Your cancer has grown or progressed after at least one prior standard treatment (or you couldn’t tolerate it)
- You must have at least one tumor spot that can be injected with a needle using touch or ultrasound (and at least one additional injectable tumor for combination parts)
- You must have measurable disease and be able to do daily activities fairly well (ECOG 0–2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.